TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03853421
Drug: Sevuparin
Normalized name: Sevuparin
DrugBank: Sevuparin (DB15007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study will consist of three dose cohorts (3, 6 and 9 mg/kg sevuparin). Subjects in each cohort will receive a single dose of sevuparin or placebo subcutaneously on Day 1.
Study: NCT02087566
Drug: 600 mg linezolid
Normalized name: linezolid 600 MG
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00356915
Drug: Itraconazole 100mg capsules
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects took two 100mg capsules once per day after a full meal. The dose dose was taken the day before the Week 12 visit.
Study: NCT00356915
Drug: Itraconazole 200mg tablets
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects took one 200mg tablet once per day after a full meal. The last dose was taken the day before the Week 12 visit.
Study: NCT03142607
Drug: Metronidazole gel
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1% Metronidazole gel
Study: NCT03142607
Drug: Chlorhexidine Gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.2% Chlorhexidene gluconate gel
Study: NCT01495026
Drug: Dutasteride (0.5mg, fasted state)
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open-label, randomized, single dose, multi-stage, cross-over study
Study: NCT01495026
Drug: Dutasteride (0.5mg, fed state)
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial formulation of Dutasteride 0.5mg
Study: NCT01495026
Drug: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FDC with 85%, 65% and 0% of the dose as enteric-coated pellets and with X and/or Y% of the dose as enteric-coated pellets (X and Y to be determined from PK results from Stage 1)
Study: NCT01495026
Drug: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FDC containing faster-release enteric-coated pellets
Study: NCT01495026
Drug: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FDC bioequivalent to Harnal-D tablets
Study: NCT01495026
Drug: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fed state)
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FDC bioequivalent to Harnal-D tablets
Study: NCT01495026
Drug: Harnal-D Tablets with water (fasted state)
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial formulation of Harnal-D Tablets
Study: NCT01495026
Drug: Harnal-D Tablets with water (fed state)
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial formulation of Harnal-D Tablets
Study: NCT01495026
Drug: Harnal-D tablets without water (fasted state)
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial formulation of Harnal-D Tablets
Study: NCT01627704
Drug: Fluoroestradiol (18F)
Normalized name: fluoroestradiol (18F)
DrugBank: Fluoroestradiol F-18 (DB15690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-4 MBq/kg body mass, one single IV injection
Study: NCT01588821
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 60 mg daily by mouth
Study: NCT02318602
Drug: Cannabidiol Oral Solution
Normalized name: cannabidiol Oral Solution
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
Study: NCT03932240
Drug: Fibrinogen Concentrate (FC)
Normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of fibrinogen concentrate will be calculated to achieve a level of 300mg/dL after drug administration.
Study: NCT02371629
Drug: Salbutamol
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients received salbutamol (100 μg) as only rescue medication
Study: NCT01073943
Drug: PicoPrep
DrugBank: Picosulfuric acid (DB09268)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PicoPrep (sodium picosulfate, magnesium oxide and citric acid) powder for oral solution consisted of 2 pouches of powder administered in a divided dose. Each PicoPrep pouch was reconstituted by mixing the contents in a cup with 5 ounces of cold water. Subjects randomized to the PicoPrep group will begin treatment (1st sachet) one day before colonoscopy between 4:00 and 6:00 PM, and will complete the treatment (2nd sachet) at least 6 hours later, between 10:00 PM and 12:00 AM. Subjects will consume approximately (5) 8 oz. glasses of clear liquids following the first sachet administration in the afternoon and (3) 8 oz. glasses of clear liquids following the second sachet administration in the evening, one day before colonoscopy.
Study: NCT01073943
Drug: HalfLytely
Normalized name: HalfLytely and Bisacodyl
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HalfLytely contains polyethylene glycol electrolyte solution (PEG-EL), sodium chloride, sodium bicarbonate and potassium chloride. The day prior to the colonoscopy procedure and after the first bowel movement or after 6 hours following administration of the bisacodyl tablets, whichever occurred first, subjects were to drink the 2 liter HalfLytely at a rate of one 8-ounce glass every 10 minutes. The entire solution was to be consumed.
Study: NCT01073943
Drug: bisacodyl
Normalized name: Bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two 5 mg bisacodyl tablets were taken in the afternoon on the day prior to the colonoscopy procedure.
Study: NCT04833036
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 180 mg/m2, ivgtt d1，q2w
Study: NCT04833036
Drug: cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 500 mg/m2, ivgtt d1，q2w
Study: NCT04938856
Drug: Lamotrigine tablet
Normalized name: Lamotrigine Tablets
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine 100 mg immediate release Tablet
Study: NCT01697332
Drug: Hyperpolarized 129Xe gas
Normalized name: xenon-129, hyperpolarized
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800cc of a gas mixture containing 129Xe and nitrogen will be inhaled by a subject. The subject will hold their breath for no more than 16 seconds while a MRI scan is performed. The gas mixture can contain between 20 and 100% xenon.
Study: NCT01334073
Drug: Axitinib plus everolimus
Normalized name: Axitinib
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will take both drugs orally, every day, without planned rest period (AX bid and EV once a day). By convention one cycle is 28 days. At the first cycle patients will take one week of AX single agent before starting EV. Patients will be treated at increasing dose levels (DLs) in successive cohorts of 3-6 patients according to the number of patients with dose limiting toxicities (DLT) until the maximum tolerated dose
Study: NCT01967225
Drug: Tedizolid Phosphate (Sivextro, BAY1192631)
Normalized name: Tedizolid
DrugBank: Tedizolid phosphate (DB09042)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: BAY1192631 solution or tablet 200 mg, once daily, Intravenous (IV) or By Mouth (PO) for 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia.
Study: NCT01967225
Drug: Linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid solution or tablet 600 mg, twice daily, every 12 ±3 hours, Intravenous (IV) or By mouth (PO) 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia.
Study: NCT01053676
Drug: Lanthanum Carbonate (Fosrenol, BAY77-1931) Granule
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: BAY77-1931 Granule TID for 4 days
Study: NCT01053676
Drug: Lanthanum Carbonate (Fosrenol, BAY77-1931) Chewable tablet
Normalized name: lanthanum carbonate Chewable Tablet
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: BAY77-1931 Chewable tablet TID for 4 days
Study: NCT01144754
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Calculated per patient
Study: NCT00661375
Drug: Nexavar (Sorafenib, BAY43-9006)
Normalized name: Nexavar
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BAY 43-9006 400mg b.i.d. Treatment will continue until progression of underlying disease, unacceptable toxicity whose causal relationship to the study drug cannot be ruled out and which requires discontinuation of the drug, or consent withdrawal.
Study: NCT03890055
Drug: Anlotinib Hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best supportive care
Study: NCT01368068
Drug: Tibolone
Normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5mg/oral/daily
Study: NCT01368068
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg/oral/daily
Study: NCT01368068
Drug: Natvia
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: serving size: 0.09g per tablet
Study: NCT02183389
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02183389
Drug: BI 1356
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04391764
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone at a dose of 50 mg per day
Study: NCT01917331
Drug: Beclometasone/Formoterol/Glycopyrrolate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Active drug tested
Study: NCT01917331
Drug: Beclometasone/Formoterol
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Active comparator
Study: NCT00408278
Drug: ATRA
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 45 mg/m2 day until CR Consolidation: 3 cycles (45 mg/m2 days 1-15) Maintenance:15 days every 3 months
Study: NCT00408278
Drug: Idarubicina
Normalized name: Idarubicina
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction: 12 mg/m2 days 2, 4, 6 and 8 Consolidation: 5 mg/m2 days 1-4 in cycle 1 and 12 mg/m2 day 1 in cycle 3.
Study: NCT00408278
Drug: Mitoxantrone
Normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Consolidation: Mitoxantrone 10 mg/m2 days 1-3 in cycle 2
Study: NCT00408278
Drug: ARA-C
Normalized name: Ara-C
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In high risk patients, consolidation with ara-C in cycles 1 and 3.
Study: NCT02680288
Drug: Lorcaserin, 10 mg
DrugBank: Lorcaserin (DB04871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral type 2C serotonergic agonist, low-dose
Study: NCT02680288
Drug: Lorcaserin, 20 mg
DrugBank: Lorcaserin (DB04871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral type 2C serotonergic agonist, high-dose
Study: NCT00488527
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will begin with a fixed, subcutaneous dose of insulin glargine, (10 U), in its commercial presentation, which will be adjusted week by week, according to the values of the glycemia when fasting (FBG), adding 2, 4, 6 or 8 units of insulin glargine over the following twelve weeks, during which the therapeutic objective should be attained, namely the glucose goal during fasting of 100 mg/dl (\<6.0 mmol/L), and the active treatment is to be continued for three more months.
Study: NCT02729961
Drug: Brentuximab Vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02729961
Drug: Ceritinib
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02242396
Drug: Telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01965925
Drug: Modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ratio of 2:1 subjects will be in the experimental arm receiving modafinil for 8 weeks.
Study: NCT02464631
Drug: Sofosbuvir + Ribavirin 1
Normalized name: Sofosbuvir
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02464631
Drug: Sofosbuvir + Ribavirin 2
Normalized name: Sofosbuvir
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02464631
Drug: Sofosbuvir + Ribavirin 3
Normalized name: Sofosbuvir
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03540095
Drug: Erector Spinae Plane Block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See arm description
Study: NCT03540095
Drug: Paravertebral Nerve Block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See arm description
Study: NCT03035812
Drug: Alkali
Normalized name: Isopto Alkaline
DrugBank: Alkaline Phosphatase (DB05768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral intake of alkali therapy whatever the formulation (alkali-based water, powder or pharmaceutics)
Study: NCT03094247
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients with severe acute malnutrition will receive a course of amoxicillin.
Study: NCT05809518
Drug: Propofol injection
Normalized name: propofol Injection
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sedation after cardiac surgery
Study: NCT05809518
Drug: Dexmedetomidine injection
Normalized name: dexmedetomidine Injection
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: sedation after cardiac surgery
Study: NCT05809518
Drug: Dexmedetomidine and Propofol
Normalized name: Propofol
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: sedation after cardiac surgery
Study: NCT00924950
Drug: Taclonex Ointment and Hydrogel Patch
Normalized name: betamethasone / calcipotriene Topical Ointment [Taclonex]
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each patient will have bilateral symmetrical psoriatic plaques. One plaque will be treated with Taclonex Ointment daily along with Hydrogel Patch daily. All treatment will be for 4 weeks.
Study: NCT00924950
Drug: Taclonex Ointment
Normalized name: betamethasone / calcipotriene Topical Ointment [Taclonex]
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taclonex ointment daily for one psoriatic plaque.
Study: NCT02009618
Drug: Rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin tablet is given as 200 mg 3x2/daily, for 10 days.
Study: NCT00244608
Drug: Budesonide/Formoterol Turbuhaler
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00244608
Drug: Budesonide Turbuhaler (Pulmicort)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00244608
Drug: Terbutaline Turbuhaler
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04193202
Drug: Gefapixant
Normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Administered twice daily as an oral tablet of 45 mg
Study: NCT03196921
Drug: Encochleated Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lipid-crystal nanoparticle formulation of amphotericin B; oral
Study: NCT01602315
Drug: BYL719 as dispersible tablets (DT)
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formulation of the oral alpha-specific PI3K inhibitor
Study: NCT04025918
Drug: Phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylephrine is a vasopressor drug that was administered when the participant's systolic blood pressure fell below 90% of baseline systolic blood pressure, with heart rate of at least 60bpm.
Study: NCT04025918
Drug: Ephedrine
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ephedrine is a vasopressor drug that was administered when the participant's systolic blood pressure fell below 90% of baseline systolic blood pressure, with heart rate of less than 60bpm.
Study: NCT00800007
Drug: ANZ-521
Normalized name: ANZ-100
DrugBank: ANZ-100 (DB05967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3x10\^7 cfu or 3x10\^8 cfu ANZ-521 in 250 mL, IV over 2 hours, every 28 days for up to 3 doses.
Study: NCT02677545
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02677545
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02677545
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01076595
Drug: Interferon beta-1b (Betaseron, BAY86-5046)
Normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betaferon 250 microgram
Study: NCT00262834
Drug: vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally, conventional surgery to follow.
Study: NCT00533390
Drug: efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600mg X 800mg QID during TB therapy with rifampicin associated with other antituberculosis drugs in patients concomitant treated for tuberculosis and AIDS
Study: NCT00354354
Drug: Combivent
Normalized name: Combivent
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized Combivent (4 mL) or saline solution (0.9% NaCl) (4 mL) will be administered once only to subjects.
Study: NCT00942682
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taken orally twice daily
Study: NCT04246047
Drug: Belantamab mafodotin
Normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate
Study: NCT04246047
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-cluster of differentiation 38 \[CD-38\] monoclonal antibody
Study: NCT04246047
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Proteasome Inhibitor
Study: NCT04246047
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Synthetic glucocorticoid with anti-tumor activity
Study: NCT00335244
Drug: L-citrulline
Normalized name: L-citrulline
DrugBank: Citrulline (DB00155)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150mg bolus X 1 after initiation of cardiopulmonary bypass followed by continuous infusion of 9mg/kg/hr IV, starting 4 hours post bolus administration and ending at 48 hours continuous infusion or discharge from the PCCU
Study: NCT01170780
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: single use of dexamethasone IV 8 mg/2 ml
Study: NCT01170780
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 ml IV
Study: NCT02076373
Drug: recombinant human Erythropoietin
Normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. administration
Study: NCT02031276
Drug: risankizumab IV
Normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: risankizumab administered by IV infusion
Study: NCT02031276
Drug: risankizumab SC
Normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: risankizumab administered by SC injection
Study: NCT01235910
Drug: Aliskiren
Normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aliskiren 75 mg once daily x 2 weeks, then aliskiren 150 mg once daily x 2 weeks, if blood pressure allows
Study: NCT02880852
Drug: Belimumab
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Belimumab will be provided as white uniform lyophilized cake in vials with unit dose strength of 400 mg/vial plus excipients (citric acid/sodium citrate/sucrose/polysorbate) for reconstitution in 4.8 milliliter sterile water for injection (SWFI). Belimumab will be administered as 10 mg/kg intravenous infusion for over 1 hour on Day 0.
Study: NCT01205009
Drug: Ovitrelle
DrugBank: Choriogonadotropin alfa (DB00097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One dose of Ovitrelle 250 mcg
Study: NCT01917123
Drug: L-Citrulline malate
DrugBank: Citrulline (DB00155)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-Citrulline malate as a 1gr powder agent, twice a day, for 2 weeks and placebo as a 1gr powder agent of O.R.S, twice a day,for 2 weeks
Study: NCT00123474
Drug: dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, 50 mg BID, indefinitely, survival study
Study: NCT00123474
Drug: dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, 70 mg BID, indefinitely, survival study
Study: NCT00123474
Drug: dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, 100 mg QD, indefinitely, survival study
Study: NCT00123474
Drug: dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, 140 mg QD, indefinitely, survival study